AzTrials
AzTrials

Weakness, MuscleMUICUAWNCT04864093

Muscular Ultrasound and Production of ICUAW

An observational study of Weakness, Muscle, run by University of Milan at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Skeletal muscle weakness is a common complication of acute respiratory failure, shock and other manifestations of critical illness or injury. ICU acquired weakness (ICUAW) - an entity defined as a bundle of critically illness neuro-myopathy and disuse atrophy - is generally diagnosed on the basis of a volitional… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Weakness, Muscle
What is being tested?
muscular ultrasound
How many people
49 participants
Where
1 siteItaly
Study dates
21 Jan 2021to 21 Oct 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: all ICU patients

Who may be able to join

  • patients admitted to ICU witha prediction of ICU stay >7 days

Who cannot join

  • Exclusion criteria included preexisting neurological weakness, pregnancy, malignancy, and those admitted for routine overnight postoperative surgical recover

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • ASST Santi Paolo carlo

    Milan, 20148

Other trials in Italy

About this study

Official title: Predicative Valute of Muscular Ultrasound in the Diagnosta of ICUAW in Critically Ill Patients

Skeletal muscle weakness is a common complication of acute respiratory failure, shock and other manifestations of critical illness or injury. ICU acquired weakness (ICUAW) - an entity defined as a bundle of critically illness neuro-myopathy and disuse atrophy - is generally diagnosed on the basis of a volitional, clinical strength evaluation, which however requires patient cooperation and ability to comprehend the assessor's instructions. As patients are often unconscious or uncooperative, due to sedation or delirium, such clinical diagnosis is often not possible or is delayed. A further subclassification of critical illness neuromyopathy can be achieved using detailed nonvolitional electrophysiological investigations, which can be challenging in the ICU as they require skilled personnel for both assessment and interpretation. An average Medical Research Council strength score (MRC-SS) combined for 12 specified muscle groups lower than 48 has been widely used for diagnosing ICUAW. Recent studies reported the clinical applicability of the MRC-SS in a general ICU population, in particular its clinical usefulness in predicting ICU and in-hospital patient outcomes . Moreover, interobserver agreement and clinical predictive value have already been showed (8). However, ICU general population is less likely to be able to cooperate with volitional strength assessment and more likely to have limited access to their extremities because of trauma, burns and treatment involving medical devices. For these reasons, MRC-SS may be confined to the later stages of ICU stay. Skeletal muscle ultrasound is used for the evaluation of muscular, tendon and joint disorders. It allows the evaluation of normal and pathological skeletal muscles through the measure of parameters reflecting size, such as cross sectional area (CSA) , and architecture by calculating the pennation angle, and it allows quick and repeated bedside evaluations. Despite such promising features, to date, there are few published studies that have reported the clinical applicability of the muscle ultrasound in prediction of ICUAW during the ICU stay. The principal aim of this study is to evaluate the variation of peripheral muscle ultrasound characteristics (such as CSA and pennation angle) during the ICU stay and its possible early predictive value of ICUAW as compared to the MRC-SS performed when patients are able to cooperate.

Read the detailed description

Skeletal muscle weakness is a common complication of acute respiratory failure, shock and other manifestations of critical illness or injury. ICU acquired weakness (ICUAW) - an entity defined as a bundle of critically illness neuro-myopathy and disuse atrophy - is generally diagnosed on the basis of a volitional, clinical strength evaluation, which however requires patient cooperation and ability to comprehend the assessor's instructions. As patients are often unconscious or uncooperative, due to sedation or delirium, such clinical diagnosis is often not possible or is delayed. A further subclassification of critical illness neuromyopathy can be achieved using detailed nonvolitional electrophysiological investigations, which can be challenging in the ICU as they require skilled personnel for both assessment and interpretation. An average Medical Research Council strength score (MRC-SS) combined for 12 specified muscle groups lower than 48 has been widely used for diagnosing ICUAW. Recent studies reported the clinical applicability of the MRC-SS in a general ICU population, in particular its clinical usefulness in predicting ICU and in-hospital patient outcomes . Moreover, interobserver agreement and clinical predictive value have already been showed (8). However, ICU general population is less likely to be able to cooperate with volitional strength assessment and more likely to have limited access to their extremities because of trauma, burns and treatment involving medical devices. For these reasons, MRC-SS may be confined to the later stages of ICU stay. Skeletal muscle ultrasound is used for the evaluation of muscular, tendon and joint disorders. It allows the evaluation of normal and pathological skeletal muscles through the measure of parameters reflecting size, such as cross sectional area (CSA) , and architecture by calculating the pennation angle, and it allows quick and repeated bedside evaluations. Despite such promising features, to date, there are few published studies that have reported the clinical applicability of the muscle ultrasound in prediction of ICUAW during the ICU stay. The principal aim of this study is to evaluate the variation of peripheral muscle ultrasound characteristics (such as CSA and pennation angle) during the ICU stay and its possible early predictive value of ICUAW as compared to the MRC-SS performed when patients are able to cooperate.

Materials and methods

Study design and ethical approval

observational, single-center study in a mixed medical and surgical ICU in a university teaching hospital. We will investigate the variation of CSA and pennation angle of rectus femoris over the ICU stay. Moreover, we will examine the clinical predictive value of these two variables as compared with MRC-SS at awakening. Patients 18 years of age and older who had been invasively ventilated for 48 hours were eligible for inclusion. Exclusion criteria included preexisting neurological weakness, pregnancy, malignancy, and those admitted for routine overnight postoperative surgical recovery. A flow diagram of the study is showed in figure 1.

Study protocol

At ICU admission (T1), patients underwent muscular ultrasound comprehensive of rectus femoris cross sectional area (RFCSA) and pennation angle, diaphragm, and parasternal intercostal end-expiratory thickness appraisal. At the same time, anthropometric data and biochemical parameters necessary for the calculations of severity score (Sequential organ failure assessment -SOFA (16); Simplified acute physiology score- SAPS II ; Acute Physiology and Chronic Health Evaluation - APACHE II ) were collected. All the same measures were repeated at day 3 (T3) and 7 (T7).

Anthropometric Assessment

Anthropometric measurements of body length and weight will be recorded at ICU admission. The actual body weight as reported by the patients when able to do it was collected. From anthropometric data, body mass index (BMI, kg/m2) will be calculated, while ideal body weight was calculated using a standard formula as previously described .

Muscular ultrasound

RFCSA will bemeasured by B-mode ultrasonography using an 8 MHz, 5.6 cm linear transducer array (MindRay TE-5 machine, Mindray Bio-Medical Electronics Co. Ltd. Shenzen, China), similar to the method described elsewhere (11). The pennation angle, the angle of insertion of muscle fascicles into the deep aponeurosis, of the rectus femoris will be measure on the longitudinal view by rotating the probe parallel to either the lateral or medial head of the muscle on the position where we measured CSA. To obtain precise measurements of muscle parameters, all measurements will be performed by the same sonographer (PF) with 5 years of experience . All data will be measure three times, and the average value will be used for further analysis.

Diaphragm end-expiratory thickness will be measure in the right hemi-diaphragm in the zone of apposition as described elsewhere . All ultrasound examinations will be performe using a 10-15 MHz linear transducer in B mode (MindRay TE-5 machine, Mindray Bio-Medical Electronics Co. Ltd. Shenzen, China) by the same trained operators (PF). The inferior border of the costophrenic sinus will be identifiy as the zone of transition from the artefactual representation of the lung to the visualization of diaphragm and liver. The expiratory thickening of the parasternal intercostal muscles will be assesse with a linear probe placed 3 cm laterally from the sternum, and oriented along the sagittal plane, between the 2nd and the 3rd ribs (22). Muscle thickness will be measure just above the pleural line between the inner and outermost hyperechogenic layers of the muscle fascial borders. Images will be recorde for a subsequent computer-assisted quantitative analysis performed by a trained investigator (MU), unaware of the ventilatory condition.

MRC-SS

The consciousness level of patients will be determine using the Richmond Agitation Sedation Scale, with a score from -1 to +1 being indicative of wakefulness. Awake patients will then required to demonstrate a positive response to simple one-stage commands. Successful completion of commands was followed by muscle strength assessment using the MRC-SS - a six-point grading scale ranging from 0 (no visible contraction) to 5 (normal power) applied to six upper- and lower-limb muscle groups bilaterally (25). The day upon which MRC-SS will be performe will be recorded. ICUAW is defined as an MRC-SS less than 48 out of a possible score of 60. A standardized protocol for performing the MRC-SS will be always followed during testing. Given the volitional nature of manual muscle testing, strong verbal encouragement will be provided during all strength assessments.

statistical analysis

The computation of the study power isbased on the primary outcome (prediction of ICU-acquired weakness). A previous study found a correlation between diaphragm ultrasound and the development of ICU-acquired weakness of r=0.3. Since the current study also assesses peripheral muscle ultrasound, we hypothesized that a stronger correlation (about twice that found in the cited study) could be found with 80% power at a 5% significance level by enrolling 47 patients.

Data will be analyzed using Stata/SE 12.0 (StataCorp, College Station, TX USA) statistical software package. Two-tailed P-values <0.05 will be considered statistically significant. Normality will be assessed by the Shapiro-Francia test. Results will be reported as mean ± standard deviation if normally distributed, or median [25-75th percentiles] otherwise, and differences will be tested with a two-sided t test or the MannWhitney U test. Categorical variables are expressed as counts and percentage and the Chi-square or Fischer exact test will be used for analysis.

Being tested
muscular ultrasound
Medical subject headings
Muscle Weakness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • muscular ultrasoundDiagnostic test

    respiratroy and muscular ultrasound

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. muscular reduction over the time

    Muscular ultrasound detect a muscles reduction over the time

    Measured: One year

Secondary outcomes (1)
  1. muscular ultrasond predictivity of ICUAW

    Muscular ultrasound evauation anticipate the diagnosta of ICUAW

    Measured: One year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Apr 2021
  2. Study start21 Jan 2021
  3. Primary completion21 Oct 2021
  4. Study completion21 Oct 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
49 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04864093
Sponsor's protocol ID
Umilan@
Acronym
MUICUAW
Status last verified
Apr 2022
First submitted
22 Apr 2021
Last updated
26 Apr 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Weakness, Muscle, run by University of Milan at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

muscular reduction over the time (time frame: One year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Apr 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in